Gain a competitive edge, advance your career
The Master of Pharmaceutical Bioengineering program (PharBE) is a part-time online degree program designed to enable working engineers, scientists, researchers and professionals in the biotechnology, pharmaceutical and related industries to explore advanced education. This interactive program covers drug discovery and design, pharmaceutics and translational pharmaceutics, clinical drug and device development, molecular and cellular biology, pathophysiology and pharmacology. Using live (synchronous), and pre-recorded (asynchronous) lectures, the program provides a path to acquire new skills, gain an edge in your current job, and receive training to transition to a new career in the biotechnology or pharmaceutical industry.
All of the professors that were listed online were highly knowledgeable and great mentors that I wanted to learn from. Mark Minie and Robbie Wong are absolutely brilliant.
In the program you get to listen to many guest speakers talk about their experience, and you have a better understanding of what types of roles there are in the pharmaceutical industry.
I made the jump to a scientist role thanks in part to my master’s from the PharBE program.
If I hadn’t taken the PharBE program I would never have known about other areas of research and development.
LEARN FROM EXPERTS IN THE FIELD
Robbie Wong
Edward Kelly
Patrick Stayton
The PharBE program gives students direct access to faculty who have first-hand experiences with the drug development process, both in academia and industry. Roberta Wong, Bioengineering teaching professor, was previously in Biopharma Industry at Amgen managing clinical trials, project and portfolio management, Abraxis Bioscience as director of corporate planning and at Agensys as director of research and a Seattle-based pharmaceutical consultant prior to joining the UW bioengineering faculty. She co-directs the program with two other UW professors. Edward Kelly, is UW professor of pharmaceutics, whose research is focused on using “organs on chips” or microphysiological systems (MPS) to model human diseases. Kelly managed the Preclinical Bioanalytics group at Targeted Genetics Corporation before joining UW’s faculty. Patrick Stayton is distinguished career professor of Bioengineering who has developed therapies and co-founded two companies to move those technologies into market. Previously, Stayton was director of the molecular engineering & Sciences institute.
The program also features upper-level industry experts from diverse backgrounds, with hands-on knowledge and experience taking drug candidates from concept to commercial market. As guest instructors they offer students a breadth of exposure across the industry.
The students also learn from each other. The program draws a broad mix of students, from those right out of undergraduate programs to bench scientists, lawyers, medical professionals and those with MBAs. Their diverse experiences create a rich learning environment. Students are encouraged to share insights from their daily work, including the manufacturing process, challenges in animal studies or experiments with drug candidates.
Apply to UW Bioengineering’s Master of Pharmaceutical Bioengineering (PharBE) program
The PharBE program has flexible options for candidates to apply to and enter the program, including priority and space-available admission.
MORE ABOUT ADMISSIONS
UW Pharmaceutical Bioengineering (PharBE) Advisory Board
The UW PharBE Advisory Board provides expert guidance to ensure our curriculum remains current and forward-looking, helping graduates advance their careers.
Advisory Board Members:
- Allison Bianchi, PhD – VP, Cell Therapy Development, Bristol Myers Squibb
- Lynnae Jackson, eMBA – VA Rondo Therapeutics
- Tarryn Haffner, PharBE – Assoc. Director, Clinical Operations, Genmab
- Chimba Mkandawire, PhD – Principal Engineer, Exponent’s Biomechanics
- Tracey Stevens, PharBE – Sr. Director, Site & Laboratory Operations, Regeneron
- Caren Tidwell, PhD – VP, Grants & Contract Management, Just-Evotec